Drug Interactions Between Antiplatelet or Novel Oral Anticoagulant Medications and Antiretroviral Medications

Annals of Pharmacotherapy

Volumn 48, Issue 6, 2014, Pages 734-740

  Egan, Gregory ^a   Hughes, Christine A ^b   Ackman, Margaret L ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ALBERTA HEALTH SERVICES   (Canada)

Author keywords

antiplatelets; antiretrovirals; drug interaction; human immunodeficiency virus infection; novel oral anticoagulants

Indexed keywords

ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; COBICISTAT; DABIGATRAN; DOLUTEGRAVIR; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PRASUGREL; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RIVAROXABAN; TENOFOVIR; TICAGRELOR;

DRUG INFORMATION; DRUG INTERACTION; EMBASE; HUMAN; IN VIVO STUDY; INTERNET; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANTI-RETROVIRAL AGENTS; ANTICOAGULANTS; DRUG INTERACTIONS; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 84899730529     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014523115     Document Type: Review

References (35)

1. Sudano I,Spicker LE,Noll G,et al.Cardiovascular disease in HIV infection.Am Heart J. 2006;151:1147-55.
2. Thompson MA,Aberg JA,Cahn P,et al.Antiretroviral treatment of adult HIV infection: 2010 recommendations of the international AIDS society USA panel.JAMA. 2010;304:321-323.
3. Frijs-Moller N,Weber R,Reiss P,et al.Results from the DAD study: cardiovascular disease risk factor in HIV patients associated with antiretroviral therapy.AIDS. 2003;17:1179-1193.
4. O'Gara PT,Kushner FG,Ascheim DD,et al.2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2013;61:e78-e140.
5. Hamm CW,Bassand JP,Agewall S,et al.ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.Eur Heart J. 2012;62:1-18.
6. Jneid H,Anderson JL,Wright RS,et al.ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation. 2012;126:875-910.
7. Skanes AC,Healey JS,Cairns JA,et al.Focused 2012 update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: recommendations for stroke prevention and rate/rhythm control.Can J Cardiol. 2012;28:125-136.
8. Plavix (clopidogrel tablets) [product monograph]. Laval, QC, Canada: sanofi-aventis. http://products.sanofi.ca/en/plavix.pdf. Accessed August 28, 2013.
9. Effient (prasugrel) [product monograph]. Indianapolis, IN: Eli Lilly and Company. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022307s002lbl.pdf. Accessed August 28, 2013.
10. Teng R.Pharmacokinetic, pharmacodynamic and pharmacogenomic profile of the oral antiplatelet agent ticagrelor.Clin Pharmacokinet. 2012;51:305-318.
11. Stangler J.Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.Clin Pharmacokinet. 2008;47:285-295.
12. Rivaroxaban [product monograph].Toronto, ON, Canada: Bayer Inc. http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=80247&lang=engAccessed Feb 5th, 2014.
13. Eliquis (apixaban) [product monograph]. Montréal, QC, Canada: Bristol-Myers Squibb. http://www.pfizer.ca/en/our_products/products/monograph/313. Accessed August 28, 2013.
14. US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Accessed June 15, 2013.
15. Rathbun RC,Liedtke MD.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Pharmaceutics. 2011;3:745-781.
16. Ancrenaz V.Pharmacokinetic interaction between prasugrel and ritonavir in health volunteers.Basic Clin Pharmacol Toxicol. 2013;112:132-137.
17. Xu C,Desta Z.In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.Drug Metab Pharmacokinet. 2013;28:362-371.
18. Bates D,Dalton B,Gilmour J,et al.Venous thromboembolism due to suspected interaction between rivaroxaban and nevirapine.Can J Hosp Pharm. 2013;66:125-129.
19. Tseng A,Foisy M.Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs.Curr Infect Dis Rep. 2012;14:67-82.
20. Effient (prasugrel) [product monograph]. Philadelphia, PA: GlaxoSmithKline. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022307s002lbl.pdf. Accessed January 4, 2014.
21. Small DS,Farid NA,Payne CD,et al.Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.Clin Pharmacokinet. 2010;49:777-798.
22. Farid NA,Jakubowski JA,Payne CD.Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.Curr Med Res Opin. 2009;25:1821-1829.
23. Htun WW,Steinhubl SR.Ticagrelor: the first novel reversible P2Y12 inhibitor.Expert Opin Pharmacother. 2013;14:237-245.
24. Zhou D,Anderson TB,Grimm SW.In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction and differential kinetics.Drug Metab Dispos. 2011;39:703-710.
25. Horn J,Hansten P.Dabigatran: a new oral anticoagulant.Pharm Times. 2010;10:59.
26. Cabral KP.Pharmacology of the new target-specific oral anticoagulants.J Thromb Thrombolysis. 2013;9:29-35.
27. Kwong LM,Tong LM.Drug interactions with rivaroxaban following total joint replacement surgery.Ann Pharmacother. 2012;46:1232-1238.
28. Raghavan N,Frost CE,Yu Z,et al.Apixaban metabolism and pharmacokinetics after oral administration to humans.Drug Metab Dispos. 2009;37:74-81.
29. Wang L,Zhang D,Raghavan N,et al.In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction sites.Drug Metab Dispos. 2010;38:448-458.
30. Vrouenraets S,Wit F,Van Tongeren J,et al.Efavirenz: a review.Expert Opin Pharmacother. 2007;8:851-871.
31. Kakuda TN,Scholler-Gyure M,Hoetelmans RM.Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.Clin Pharmacokinet. 2011;50:25-39.
32. Celsentri (maraviroc) [product monograph]. Montréal, QC, Canada: Pfizer Canada Inc. http://files.investis.com/media/Files/Canada/celsentr-pm-2011-02-22.pdf. Accessed August 28, 2013.
33. Rachlis A,Angel JB,Harris M,et al.Optimal use of raltegravir (Isentress®) in the treatment of HIV-infected adults: Canadian Consensus Guidelines.Can J Infect Dis Med Microbiol. 2009;20:e67-e80.
34. Tivicay (dolutegravir) [product monograph]. Laval, QC, Canada: ViiV Healthcare ULC. http://webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00022573. Accessed December 28, 2013.
35. Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate tablets) [product monograph]. Mississauga, ON, Canada: Gilead Sciences. http://www.gilead.ca/pdf/ca/stribild_pm_english.pdf. Accessed August 28, 2013.